{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:51:30Z","timestamp":1790088690768,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ejim.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T17:37:04Z","timestamp":1551461824000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure \u2013 A danish nationwide registry-based study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-8627","authenticated-orcid":false,"given":"Charlotte","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W\u00e6de","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida E.","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar H.","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-6131","authenticated-orcid":false,"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejim.2019.02.014_bb0005","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.05.020415","article-title":"Global Health epidemiology reference G. Global and regional estimates of COPD prevalence: systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1183\/09031936.00044411","article-title":"Unrecognised ventricular dysfunction in COPD","volume":"39","author":"Macchia","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2019.02.014_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/COPD.S32330","article-title":"Epidemiology of chronic obstructive pulmonary disease: a literature review","volume":"7","author":"Rycroft","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.ejim.2019.02.014_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002546","article-title":"Pulmonary artery enlargement is associated with right ventricular dysfunction and loss of blood volume in small pulmonary vessels in chronic obstructive pulmonary disease","volume":"8","author":"Wells","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.ejim.2019.02.014_bb0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jacc.2013.04.091","article-title":"Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension","volume":"62","author":"Hilde","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.02.014_bb0035","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a Network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ehjcvp\/pvw027","article-title":"Is the use of renin-angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? a systematic review and meta-analysis","volume":"3","author":"Andersson","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.ejim.2019.02.014_bb0050","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1378\/chest.103.5.1354","article-title":"Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease","volume":"103","author":"Sajkov","year":"1993","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ejim.2019.02.014_bb0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chest.2017.02.002","article-title":"The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study","volume":"152","author":"Raymakers","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ejim.2019.02.014_bb0060","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3892\/etm.2013.1001","article-title":"Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage","volume":"5","author":"Shi","year":"2013","journal-title":"Exp Ther Med"},{"issue":"8","key":"10.1016\/j.ejim.2019.02.014_bb0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejim.2019.02.014_bb0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.ejim.2019.02.014_bb0075","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Pottegard","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"11","key":"10.1016\/j.ejim.2019.02.014_bb0080","doi-asserted-by":"crossref","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundboll","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2019.02.014_bb0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.ejim.2019.02.014_bb0090","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.rmed.2011.01.012","article-title":"Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry","volume":"105","author":"Thomsen","year":"2011","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.ejim.2019.02.014_bb0095","first-page":"798","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization global initiative for chronic obstructive lung disease (GOLD): executive summary","volume":"46","author":"Pauwels","year":"2001","journal-title":"Respir Care"},{"issue":"7","key":"10.1016\/j.ejim.2019.02.014_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201208-1565OC","article-title":"Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease","volume":"187","author":"Ekstrom","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"42","key":"10.1016\/j.ejim.2019.02.014_bb0105","doi-asserted-by":"crossref","first-page":"73000","DOI":"10.18632\/oncotarget.20304","article-title":"Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejim.2019.02.014_bb0110","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease","volume":"47","author":"Mancini","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.02.014_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1465-9921-10-45","article-title":"Impact of statins and ACE inhibitors on mortality after COPD exacerbations","volume":"10","author":"Mortensen","year":"2009","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.ejim.2019.02.014_bb0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/15412555.2015.1099620","article-title":"Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis","volume":"13","author":"Pavasini","year":"2016","journal-title":"COPD"},{"issue":"10","key":"10.1016\/j.ejim.2019.02.014_bb0125","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinternmed.2010.112","article-title":"Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease","volume":"170","author":"Rutten","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2019.02.014_bb0130","doi-asserted-by":"crossref","first-page":"d2549","DOI":"10.1136\/bmj.d2549","article-title":"Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study","volume":"342","author":"Short","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejim.2019.02.014_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.ejim.2019.02.014_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012292","article-title":"Beta-blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (betaLOCK COPD): a randomised controlled study protocol","volume":"6","author":"Bhatt","year":"2016","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.ejim.2019.02.014_bb0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/thorax.58.7.629","article-title":"Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study","volume":"58","author":"Kanazawa","year":"2003","journal-title":"Thorax"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2019.02.014_bb0150","first-page":"47","article-title":"Influence of ACE inhibition on pulmonary haemodynamics and function in patients in whom beta-blockers are contraindicated","volume":"62","author":"Bertoli","year":"1986","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ejim.2019.02.014_bb0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1465-9921-6-88","article-title":"Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease","volume":"6","author":"Morrell","year":"2005","journal-title":"Respir Res"},{"issue":"5\u20136","key":"10.1016\/j.ejim.2019.02.014_bb0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00508-005-0333-z","article-title":"The link between angiotensin-converting enzyme genotype and pulmonary artery pressure in patients with COPD","volume":"117","author":"Tkacova","year":"2005","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/15412555.2012.727047","article-title":"Angiotensin-converting enzyme I\/D polymorphism is associated with COPD risk in Asian population: evidence from a meta-analysis","volume":"10","author":"Li","year":"2013","journal-title":"COPD"},{"issue":"19","key":"10.1016\/j.ejim.2019.02.014_bb0170","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/CIRCULATIONAHA.115.019130","article-title":"Lipophilic statins and aldosterone secretion: a bridge too far?","volume":"132","author":"Andersson","year":"2015","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ejim.2019.02.014_bb0175","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Canadian Institutes of Health R. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.02.014_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/COPD.S76061","article-title":"Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial","volume":"10","author":"John","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"11","key":"10.1016\/j.ejim.2019.02.014_bb0185","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.rmed.2015.06.005","article-title":"The role of pulmonary arterial stiffness in COPD","volume":"109","author":"Weir-McCall","year":"2015","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.ejim.2019.02.014_bb0190","first-page":"879","article-title":"Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis","volume":"30","author":"Caldeira","year":"2014","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2019.02.014_bb0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.healun.2015.10.002","article-title":"Anticoagulation in patients with pulmonary arterial hypertension: an update on current knowledge","volume":"35","author":"Roldan","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ejhf.199","article-title":"Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study","volume":"17","author":"Goudie","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.ejim.2019.02.014_bb0205","first-page":"104","article-title":"Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data","volume":"38","author":"Krogager","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ejim.2019.02.014_bb0210","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.ejim.2019.02.014_bb0215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ejim.2019.02.014_bb0220","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejim.2019.02.014_bb0225","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.ejim.2019.02.014_bb0230","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519300585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519300585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:29:29Z","timestamp":1760606969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620519300585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":45,"alternative-id":["S0953620519300585"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.02.014","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure \u2013 A danish nationwide registry-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}